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I. INTRODUCTION:       
In the recent years a logic treatment alternative for the 
patients who cannot tolerate the oral administration has 
been utilized for the concurrent minimization of the 
gastro intestinal disorders caused by local anesthetics, 
anti haemerrhoidal agents, anti anemic agents, anti 
fungal and anti bacterial agents, anti asthmatic agents , 
anti psychotic agents and a  majority of the natural and 
synthetic drugs. Rectal route of administration is 
especially used for infants and children who have the 
difficulty in swallowing the dosage forms through oral 
route. 
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.         A suppository is a medicated solid dosage form 
generally intended for use in the rectum, vagina, and to 
lesser extent, the urethra. Rectal and urethral 
suppositories usually employs vehicles that melt of 
soften at body temperature, whereas vaginal 
suppositories sometimes called pessaries are also made 
as compressed tablets that disintegrate in the body 
fluids 
2
 Bases acts as the vehicles or carriers of drugs. A 
variety of substances has been as suppository bases 
from the commencement of the history of suppository. 
Their use was governed by the factor of their 
availability rather than scientific approach. These bases 
play an important role in release of medication they 
hold and therefore availability of drug. 
            Zidovudine (ZDV), is an important drug used 
for treatment of HIV infection. It belongs to the family 
of nucleoside analogue reverse transcriptase inhibitors 
(NRTIs) The effectiveness of ZDV in the treatment of 
HIV infection is due to its selective affinity for HIV 
reverse transcriptase as opposed to human DNA 
polymerases. Since HIV is capable of mutating and thus 
of developing resistance to the drug. Zidovudine is an 
FDA approved drug for clinical use in the treatment of 
adults and children with HIV infections or including 
with the combination of other anti viral agents. This 
drug is typically administered in the form of tablets, 
capsule and an oral solution. The drug has a short half 
life of about 3 hours and it necessitates the frequent 
administration. In order to over the drug resistance the 
present research work deals with the development of 
suppositories by incorporating zidovudine. 
II. MATERIALS AND METHODS : 
1. Materials: Zidovudine was procured as a gift 
sample from Hetero Labs, Hyderabad. All other 
chemicals and solvents were of analytical grade and 
used as procured. 
2. Experimental methodology: 
A] Calibration of the suppository mould:
 4
  
Mould calibration was performed .Each mould of 1gm 
capacity was calibrated before the actual preparation by 
a set of blank suppositories containing the molten base 
alone. The product is weighed and the mean weight is 
taken as the true capacity of the suppository mould. The 
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calibration procedure is repeated before every 
suppository formulations preparation. The calibrated 
mould capacities ranged from 1to2gms. 
B] Preparation of suppositories:
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Melt Fusion method: Drug displacement values of the 
bases used were first determined and the amount of 
drug required was calculated. The drug powder was 
passed through a mesh sieve of 100 μm prior to its 
incorporation into the base. This method involves first 
melting the suppository base, and then dispersing or 
dissolving the drug in the melted base. The mixture is 
removed from the heat and poured into a prelubircated 
suppository mold. When the mixture has congealed, the 
suppositories are removed from the mold. Tween-80 
was incorporated in the formulation to enhance the 
release of the drug from the formulation. The 
compositions of the formulation batches were given in 
the table 1 
 
Table1: Formulation table of zidovudine suppositories (All values are in percentages) 
S.N INGREDIENTS F1 F2 F3 F4 F5 
1 Zidovudine 1 1 1 1 1 
2 Glycerin 70 60 50 70 70 
3 Gelatin 10 10 10 10 10 
4 Purified water 20 20 20 20 20 
5 Tween80 - - - 1 2 
 
C] Evaluation of zidovudine suppositories: 
Physical Dimension
7 
The width and length of randomly 
selected suppositories were measured. 
Weight Uniformity About 20 suppositories were taken 
and the average weight was determined. Not more than 
two individual suppositories should deviated by 10%.  
Crushing Strength
9 
The crushing strength was 
determined for measuring fragility or brittleness of 
suppositories, which assessed the suppositories whether 
they would be able to withstand the hazards of packing, 
transporting and normal handling are not.  
Drug Content Uniformity
10
 
Uniformity of drug content was confirmed by analyzing 
the drug content in equal batch after dissolving the 
suppositories in 0.1N NaOH and the drug content was 
determined at 450 nm. 
The results were tabulated in Table-3 
In Vitro Drug Release Studies 
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The dissolution of Zidovudine was studied the using 
USPXXI dissolution apparatus employing basket stirrer. 
Zidovudine suppositories were placed dissolution 
medium contain 0.1N NaOH solution. The rpm was 
adjusted to 50 and a temperature of 37
o
c was 
maintained throughout the experiment. A 5 ml of 
sample was withdrawn at various time intervals and 
diluted with 0.1N NaOH The volume of the dissolution 
medium was kept constant by replacing the withdrawn 
volume of the sample with equal volume of fresh 
dissolution medium maintained at the same 
temperature. A minimum of triplicate release rate 
determinations were made for each suppository 
preparation. and analyzed using UV spectrometer. The 
results of the drug release were given in Table-4 
III. RESULTS AND DISCUSSION:  
Vaginal suppositories of zidovudine, an antiretroviral 
drug, were prepared by fusion method using Glycero-
gelatin and emulsified glycerogelatin as bases .The 
prepared suppositories were evaluated for appearance, 
weight variation ,drug content uniformity, 
liquefaction/softening time, invitro dissolution. The 
previously calibrated moulds (1gm capacity)were used 
for the preparation. The calibrated mould capacities 
displacement values ranged from 0.95 to 1.02g.All the 
suppositories were free from cracks and fissures by 
appearance. All the longitudinal sections of the 
suppositories were identified clear and plain. Also the 
prepared suppositories were evaluated for weight 
uniformity and the results are given in table. The 
percentage deviations from the mean weights of all 
batches were found to be within the prescribed limits 
(mean weight ±5to±7.5%) as per Indian pharmacopoeia. 
The drug content was found to be in the range of 97 to 
99%.This was also found to be within the limits. The 
standard deviation values indicated uniform drug 
content present within the prepared suppositories. The 
softening time is the time for which the suppositories 
withstand the body temperature at 37°C.The 
disintegration range was observed to be 4 to 5 min, but 
the emulsified medicated suppositories  exhibits no 
liquefaction at that temperature. Invitro dissolution 
studies on the designed formulations were carried out in 
pH7.4 phosphate buffer and the various dissolution 
parameters were determined. The results obtained are 
shown in Table and the dissolution profiles were shown 
in figures. The data reveals that Glycero-gelatin 
suppositories(F1-F3 released zidovudine upto 83-87% 
and the emulsified glycerogelatin suppositories(F4-F5) 
released the drug upto 90%.As the emulsifier 
concentration is increased the drug release was 
decreased in emulsified glycero-gelatin suppositories 
whereas in glycerogelatin suppositories the drug release 
was decreased by the increase of glycerin composition 
,in case the release rate decreases because of the high 
molecular weight and the complex polymer structure of 
gelatin.
 
Priya et al                                       Journal of Drug Delivery & Therapeutics. 2015; 5(3):72-75 74 
© 2011-15, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Table 3: Physicochemical evaluation of suppositories 
Formulation 
Code 
Crushing 
strength(gm) 
Drug content 
%±SD 
Weight 
uniformity(gm) 
Physical 
lenghth(cm) 
Dimension 
width(cm) 
Disintegration 
time(min) 
F1 500±0.18 97.99±0.89 0.850 1.813 0.890 4.08 
F2 150±0.23 98.56±0.12 0.858 1.811 0.888 5.07 
F3 250±0.45 99.64±0.88 0.844 1.813 0.889 5.00 
F4 450±0.24 99.89±0.74 0.852 1.814 0.898 5.62 
F5 500±0.21 99.06±0.15 0.700 1.814 0.899 4.89 
 
Table4: Drug release profile of zidovudine suppositories 
TIME % DRUG RELEASED 
 F1 F2 F3 F4 F5 
5 48.84 45.5 42.15 40.48 49.05 
10 65.57 53.86 58.86 50.52 52.21 
15 67.24 65.57 65.58 65.27 68.55 
30 68.92 70.50 67.24 67.24 70.25 
45 72.96 75.61 68.92 70.50 75.52 
60 75.52 77.28 75.21 72.26 79.44 
90 83.92 80.63 82.30 85.30 85.69 
120 83.91 84.23 84.21 87.52 90.45 
 
 
 
 
Figure 1: Dissolution Profile of Best formulation F5 
 
IV. CONCLUSION:  
The present study indicates that it is possible to design 
vaginal suppositories for the drug Zidovudine, 
employing the water soluble polymeric base like 
Glycero-gelatin base. Also this study identifies that by 
the addition of emulsifiers the drug release profile was 
modified when compared to Non-emulsified 
Zidovudine Suppositories. The drug release is nearly 
first order. However, this study needs Invivo studies in 
the animal models to ascertain the relative 
bioavailability of zidovudine suppositories as a 
promising platform as dosage form.  
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